We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Neurodevelopmental Disorders Diagnosed with RNA-Sequencing

By LabMedica International staff writers
Posted on 23 Jan 2020
Cornelia de Lange syndrome (CdLS) is a genetic disorder and people with this syndrome experience a range of physical, cognitive, and medical challenges ranging from mild to severe. More...
The syndrome has a widely varied phenotype, meaning people with the syndrome have varied features and challenges.

The typical features of CdLS include thick or long eyebrows, a small nose, small stature, developmental delay, long or smooth philtrum, thin upper lip and downturned mouth. Neurodevelopmental disorders represent a frequent indication for clinical exome sequencing. Fifty percent of cases, however, remain undiagnosed even upon exome reanalysis.

Scientists at The Children’s Hospital of Philadelphia (Philadelphia, PA, USA) and their colleagues assessed Genotype–Tissue Expression project transcriptome data for human B-lymphoblastoid cell lines (LCL), blood, and brain for neurodevelopmental Mendelian gene expression. Detection of abnormal splicing and pathogenic variants in these genes was performed with a novel RNA-seq diagnostic pipeline and using a validation of 10 CdLS-LCL cohort and a test cohort of five patients who carry a clinical diagnosis of CdLS, but negative genetic testing.

The team reported that LCLs share isoform diversity of brain tissue for a large subset of neurodevelopmental genes and express 1.8-fold more of these genes compared with blood (LCL, n = 1,706; whole blood, n = 917). This enables testing of more than 1,000 genetic syndromes. The RNA-seq pipeline had 90% sensitivity for detecting pathogenic events and revealed novel diagnoses such as abnormal splice products in NIPBL and pathogenic coding variants in BRD4 and ANKRD11.

The investigators selected 10 LCLs from CdL syndrome patients with known pathogenic mutations in four genes and ran them through their transcriptome sequencing pipeline, restricting their analysis to 14 disease-causing genes. Overall, they were able to call nine of the 10 pathogenic variants, missing one nonsense variant, probably due to nonsense-mediated decay of the transcript. For one of the patients, they uncovered a mutation in a second gene, leading to an additional diagnosis with a syndrome that has overlapping clinical features with CdL syndrome.

The scientists tested their approach on five unsolved patient cases that had negative genetic testing and were suspected to have CdL syndrome or a related condition. For three of these, they obtained a genetic diagnosis, two abnormal splice events in NIPBL and one missense variant in BRD4. The BRD4 variant could have been detected by a DNA-based test, they noted, if the gene had been known at the time of the test. The authors concluded that the LCL transcriptome enables robust frontline and/or reflexive diagnostic testing for neurodevelopmental disorders. The study was published on January 8, 2020 in the journal Genetics in Medicine.

Related Links:
The Children’s Hospital of Philadelphia


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.